Program
HRS-7249
A development code. Also written as “HRS-7249 Injection”, “HRS-7249 injection set” and “HRS-7249 injection”.
In Jiangsu HengRui Medicine's pipeline, ApoC3 siRNA
. Its studies are mostly in Hyperlipidemias · Hypertriglyceridemia, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 43 open or running | phase 2since Jul 27, 2025 | Jul 16, 2024 | Jun 2027phase 2 · NCT07308392 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7249
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2024First study: phase 1 study in HyperlipidemiasFirst studyNCT06541457 · 48 enrolled · China
- Jul 27, 2025Phase 2 study in HyperlipidemiasNCT07100418 · 224 enrolled · China
- Dec 15, 2025Phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392 · 119 enrolled · China
- Aug 21, 2026Phase 2 study in HyperlipidemiasNCT07799688 · 400 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392
- Oct 15, 2028Primary completion: phase 2 study in HyperlipidemiasNCT07799688
TargetBeta
“ApoC3 siRNA”the company's pipeline, read by Claude · source
“This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants.”study summary, read by Claude · the study
Other programs on APOC3
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07799688Hyperlipidemias · China | 2 | Recruiting | Oct 15, 2028 | 400 |
| NCT07308392Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis · China | 2 | Active, not recruiting | Jun 2027 | 119 |
| NCT07100418Hyperlipidemias · China | 2 | Active, not recruiting | Sep 2026 | 224 |
| NCT06541457Hyperlipidemias · China | 1 | Completed | Jul 30, 2025 | 48 |
How it is read
Names in the registry
- “HRS-7249 Injection”, 3 entries
- “HRS-7249 injection set”, 1 entry
- “HRS-7249 injection”, 1 entry
Codes read as this program: HRS7249.
Conditions, from the studies’ own filings
- Hyperlipidemias, 3 studies
- Hypertriglyceridemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.